- Report
- May 2024
- 160 Pages
Global
From €5708EUR$5,999USD£4,814GBP
- Report
- February 2024
- 180 Pages
Global
From €5232EUR$5,499USD£4,413GBP
- Report
- February 2024
- 180 Pages
Global
From €5232EUR$5,499USD£4,413GBP
- Report
- September 2023
- 200 Pages
Global
From €2854EUR$2,999USD£2,407GBP
- Report
- April 2023
- 147 Pages
Global
From €5708EUR$5,999USD£4,814GBP
The Leukemia Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat leukemia, a type of cancer of the blood and bone marrow. These drugs are used to reduce the number of cancer cells in the body, and to prevent the spread of the disease. Commonly used drugs include chemotherapy, targeted therapy, and immunotherapy.
Chemotherapy is a type of drug that works by killing cancer cells. Targeted therapy is a type of drug that works by targeting specific molecules in cancer cells, and immunotherapy is a type of drug that works by stimulating the body's immune system to fight cancer cells.
The Leukemia Drugs market is highly competitive, with many companies competing for market share. Some of the major players in the market include Novartis, Pfizer, Bristol-Myers Squibb, Celgene, and Amgen. Show Less Read more